MLex Comment: Takeda likely to seek EC approval for Nycomed buy, expected focus on digestive disorder drugs
Japanese drug company Takeda Pharmaceuticals’ buy-out of Swiss rival Nycomed would likely require European Commission merger approval, given the companies’ respective revenues. The regulatory scrutiny is expected to focus on overlaps...To view the full article, register now.
Already a subscriber? Click here to view full article